The US Food and Drug Administration has approved the first-ever generic glucagon injection kit for the treatment of severe hypoglycemia in patients with diabetes and as a diagnostic aid.. The FDA ...

The generic product is supplied as 6mg/mL solution in a prefilled, single-patient-use pen. Each pen delivers doses of 0.6mg, 1.2mg, or 1.8mg in 2- or 3-count package sizes.

The generic product is supplied as 6mg/mL solution in a prefilled, single-patient-use pen. Each pen delivers doses of 0.6mg, 1.2mg, or 1.8mg in 2- or 3-count package sizes.

Today, the U.S. Food and Drug Administration approved the first generic of glucagon for injection USP, 1 mg/vial packaged in an emergency kit, for the treatment of severe hypoglycemia (very low ...

Hikma’s Liraglutide Injection is supplied in an 18mg/3mL prefilled, single-patient-use pen that delivers doses of 0.6mg, 1.2mg, or 1.8mg in packages of 2 and 3 injection pens.

Amphastar's generic is a synthetic peptide product that the FDA has deemed to be bioequivalent and thus therapeutically equivalent to Eli Lilly’s Glucagon Emergency Kit for Low Blood Sugar.

Amneal obtains FDA OK for generic Byetta, ... which is the company’s first generic injectable glucagon-like peptide-agonist and ... The approval of exenatide 1.2 ml and 2.4 ml prefilled pen ...

The FDA has approved the first generic glucagon for injection, commonly used to treat severe hypoglycemia in individuals with diabetes taking insulin, according to an agency press release. The ...

The US Food and Drug Administration has approved the first generic referencing Victoza (liraglutide; Hikma Pharmaceuticals), a glucagon-like peptide-1 (GLP-1) receptor agonist indicated to improve ...

Glucagon to treat severe hypoglycemia is available in a generic formula for the first time in 20 years. Patients with diagnoses of diabetes mellitus are at risk for hypoglycemia (very low blood ...